Kyphoscoliosis Surgery: Blood Conservation and Analgesia

Sponsor
Mansoura University (Other)
Overall Status
Completed
CT.gov ID
NCT03319563
Collaborator
(none)
52
1
2
6
8.7

Study Details

Study Description

Brief Summary

Since the first spinal fusion by Hibbs 1911, yet anesthesia for correction of scoliosis is challenging due to frequently associated co-morbidities, the extensive nature of surgery and liability for many complications. Among the major concerns for anesthesiologists are the pain and bleeding. Scoliosis correction accounts for massive blood loss that may exceed more than half of blood volume. There are many strategies for blood conservation; however sometimes some of them may not be suitable. For analgesia, the most frequently loco regional analgesic techniques in spine surgery are intrathecal, epidural or local infiltration techniques. infiltration data reviled inconclusive and heterogeneous results. Our purpose is to optimize blood conservation and analgesia through anatomically based modification of the infiltration technique.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

The most frequently loco-regional analgesic techniques in scoliosis surgery are intrathecal, epidural, caudal morphine, or local infiltrations techniques including ultrasound guided thoracolumbar interfascial plane block. however these techniques possess some limitations in scoliosis surgery. Local anesthetic infiltration was first applied over 35 years ago in lumbar spine surgery as a reliable technique for pain relief. However meta-analysis of data reviled inconclusive and heterogeneous efficacy results.This conflict arise from the differences in the technique and drugs.There are three levels of infiltration; subcutaneous, muscular and perineural. Its timing either pre-incision or post-surgery. Generally the preemptive and deep infiltration offer better analgesia when compared with post-surgical and superficial forms. Different drugs including local anesthetics, epinephrine and adjuvants can be given as a single injection or infusion. Doses and volumes are also different, usually ranging from 10 to 30 ml at a concentration of 0.25% Bupivacaine. the use of epinephrine helps bleeding control Concomitantly, unlike the other techniques, bupivacaine infiltration was combined at three levels in this study; subcutaneous, muscular and neural paravertebral to provide sensory, motor and sympathetic blockade all together. In addition, this drug combination may help to maintain spinal cord perfusion by avoiding deliberate hypotension. The high volume sufficient for proper tissue infiltration combined at three anatomically guided levels for three types of nerves has not been described so far. This research may benefit all spine surgery patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
High Volume, Multilevel Local Anesthetic-Epinephrine Infiltration in Kyphoscoliosis Surgery: Blood Conservation and Analgesia
Actual Study Start Date :
Apr 11, 2017
Actual Primary Completion Date :
Oct 10, 2017
Actual Study Completion Date :
Oct 10, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: local anesthetic-epinephrine group

after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels: Subcutaneous: before incision at a volume 20 ml/10 cm/side. Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume. Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration.

Drug: Local anesthetic-epinephrine
Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg. Lidocaine 5 mg/Kg. Epinephrine 5 mcg/ml of the total volume. Add normal saline to a total volume of 100 ml/10 cm of the wound length.
Other Names:
  • infiltration group
  • Placebo Comparator: saline group

    after general anesthesia, the same infiltration volume and technique using normal saline.

    Drug: Saline
    normal saline 100 ml/10 cm of the wound length
    Other Names:
  • control group
  • Outcome Measures

    Primary Outcome Measures

    1. Estimated blood loss [Intraoperative]

      milliliter

    2. Total Morphine consumption. [during first 24 hours postoperatively.]

      milligram

    Secondary Outcome Measures

    1. The surgical field visualization for subcutaneous incision [Intraoperative, 10 minutes after skin incision.]

      measured by Fromme's operative visibility scale (0-5) ,5: Massive uncontrollable bleeding, Surgery impossible. 4: Heavy but controllable. 3: Moderate bleeding , 2: Moderate bleeding but without interference with accurate dissection. 1: Bleeding, so mild, No suctioning. 0: No bleeding,

    2. The surgical field visualization for muscular dissection [Intraoperative, 30 minutes after the thoracolumbar fascia incision,]

      measured by Fromme's operative visibility scale (0-5) ,5: Massive uncontrollable bleeding, Surgery impossible. 4: Heavy but controllable. 3: Moderate bleeding , 2: Moderate bleeding but without interference with accurate dissection. 1: Bleeding, so mild, No suctioning. 0: No bleeding,

    3. The surgical field visualization for nails insertion [Intraoperative, 30 minutes after the first nail insertion.]

      measured by Fromme's operative visibility scale (0-5) ,5: Massive uncontrollable bleeding, Surgery impossible. 4: Heavy but controllable. 3: Moderate bleeding , 2: Moderate bleeding but without interference with accurate dissection. 1: Bleeding, so mild, No suctioning. 0: No bleeding,

    4. The surgical field visualization for osteotomy [Intraoperative, 20 minutes after the first osteotomy]

      measured by Fromme's operative visibility scale (0-5) ,5: Massive uncontrollable bleeding, Surgery impossible. 4: Heavy but controllable. 3: Moderate bleeding , 2: Moderate bleeding but without interference with accurate dissection. 1: Bleeding, so mild, No suctioning. 0: No bleeding,

    5. The operative duration [Intraoperative]

      minutes, from the start of anesthesia induction to extubation times

    6. The number of blood transfusion unites. [intraoperative]

      unites of packed red blood cells

    7. Nitroglycerin consumption [Intraoperative]

      milligram

    8. Fentanyl consumption [intraoperative]

      microgram

    9. Atracurium consumption [intraoperative]

      milligram

    10. Propranolol consumption [intraoperative]

      milligram

    11. Mean blood pressure (MBP) [basal, 5 minutes after the onsite of infiltration, 3 minutes after the onsite of skin incision, then after 30, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes from the start of anesthesia.]

      millimeter mercury

    12. Mean heart rate (HR) [basal, 5 minutes after the onsite of infiltration, 3 minutes after the onsite of skin incision, then after 30, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes from the start of anesthesia.]

      beats per minute

    13. Inhalational isoflurane concentration [intraoperative: at 30, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes from the start of anesthesia induction.]

      percent

    14. The number of hypertensive episodes [intraoperative]

      defined as more than 25% rise of MBP than the basal, provided as total number

    15. The number of tachycardic episodes [intraoperative]

      defined as more than 25% rise of HR than the basal, provided as total number

    16. Ephedrine consumption [intraoperative]

      milligram

    17. The total amount of fluid utilization. [intraoperative]

      milliliter

    18. Visual analog score [postoperative at 1,4,8,12,16, 20, 24 hours]

      scale (0-10), 0= no pain

    19. the time to first analgesic request [postoperative for 24 hours]

      minutes

    20. Opioid request episodes [postoperative for 24 hours]

      number

    21. Ambulation time [postoperative, the first test after 12 hours, then every 8 hours, up to 72 hours.]

      hours to the time of first standing alone after the operation.

    22. Hospital stay [postoperative, till the time of signed discharge order. up to 10 days]

      days until the discharge time with the ability to walk, eat, controlled pain.

    23. the Incidence of wound complications. [postoperative till 2 weeks]

      infection, dehiscence, seroma, hematoma, bleeding

    24. Surgeon satisfaction with the operative filed [within 2 hours from the end of operation]

      score (0-10), 10 is the best

    25. Patient satisfaction with analgesia [24 hours after the end of surgery]

      score (0-10), 10 is the best

    26. Urine output [intraoperative]

      milliliter

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Kyphoscoliosis patients subjected for spinal correction.

    2. Age 8-18 years.

    3. American Society of Anesthesiologists I-II status.

    Exclusion Criteria:
    1. Patient or parents refusal.

    2. Infection at surgical site.

    3. Hypersensitivity to amide local anesthetics.

    4. Coagulopathy.

    5. Blood diseases as sickle cell anemia, hemophilia, idiopathic thrombocytopenic purpura.

    6. Sever cardiac, respiratory, renal or hepatic impairment.

    7. Presence of communication barrier.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mansoura University Hospital and Delta Hospital Mansourah Dakahlya Egypt 35516

    Sponsors and Collaborators

    • Mansoura University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alaa Mazy Mazy, Associate professor of anesthesia and surgical intensive care, Mansoura University
    ClinicalTrials.gov Identifier:
    NCT03319563
    Other Study ID Numbers:
    • R/17.02.85
    • PACTR201703002123104
    First Posted:
    Oct 24, 2017
    Last Update Posted:
    Oct 26, 2020
    Last Verified:
    Oct 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2020